The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.
about
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDA review of nebulized drug delivery in COPDEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by agePatient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Olodaterol: a review of its use in chronic obstructive pulmonary disease.24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.Systematic review comparing LABA, olodaterol, and indacaterol: limitations.Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
P2860
Q26775244-1B6FF199-8986-489B-8B74-7877728ABB77Q26778685-5B9240F8-C327-4C03-91B4-4A3C807D13E9Q28075295-55CC7D0B-DC88-4797-8E79-54D04D4F13D4Q33783760-2628C5CC-11B6-4231-9F67-58C939E3743BQ34011640-90E6FB14-8A54-458A-AEF8-267441C385BAQ34386867-F417DA2A-C0B8-43AC-8350-26DE74C8F5F1Q35344118-CBEE8C5D-DA69-4AA0-B9EE-66561F13D4F8Q35538249-3B2A034D-AAFF-49A2-B97A-923FE9095782Q35802628-54ACCAD8-2033-48FA-B781-004168604001Q35875281-CBC11D96-86F4-4D97-A1F7-9B645F28E123Q35965128-8D77ADFC-2D45-4294-810E-B9772FCB4346Q35994264-78D43345-038C-42D5-8D12-AAC5E355B1FBQ36158846-8430A0CF-B862-407F-A355-39ED523ED36EQ36652462-01FBCAB3-3AAD-41ED-A475-5FDBC298A77EQ37397852-182581AE-3038-4716-89AC-4AF1381331ADQ38352425-FE0E7A4F-C4D8-4DE6-8A19-5882B77C9EE2Q38379269-177A065D-63E0-4F1A-9922-EB3F56FD1117Q38618200-DA963E82-E551-4D6F-8C76-FF1DA67F07DEQ38690660-7B8574F1-E5F0-4F40-AD5A-3E1472EB47DCQ38982942-CBD76246-E5A8-44DA-9CC1-8468CE2AE5B3Q39037235-C60D50CA-F0D9-4686-9E87-E5207D5B53B4Q39627403-DCB866B0-529A-4E40-B175-492FA37B1D9AQ39674585-AD086A82-E005-47CF-A803-38EE1E62016EQ42634011-BDE00838-FBE5-452E-83D0-774D56CA8BFFQ47375559-552A0250-D208-42AB-AF5F-4F043BE4B020
P2860
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@ast
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@en
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@nl
type
label
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@ast
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@en
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@nl
prefLabel
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@ast
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@en
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@nl
P2093
P2860
P921
P356
P1433
P1476
The 24-h FEV1 time profile of ...... two 6-week crossover studies.
@en
P2093
Alan Hamilton
Craig LaForce
Gregory J Feldman
Jonathan A Bernstein
Lawrence Korducki
Michael C Nivens
P2860
P2888
P356
10.1186/2193-1801-3-419
P577
2014-08-09T00:00:00Z
P6179
1002184046